Brain And Reproductive Development Affected By Compounds From Soy, New Study Shows
Main Category: Pregnancy / ObstetricsAlso Included In: Endocrinology; Neurology / Neuroscience; Biology / Biochemistry
Article Date: 02 Aug 2008 - 0:00 PDT
|
|
| Patient / Public: | ![]() |
4.5 (2 votes) |
| Healthcare Prof: | ![]() |
3 (1 votes) |
Two hormone-like compounds linked to the consumption of soy-based foods can cause irreversible changes in the structure of the brain, resulting in early-onset puberty and symptoms of advanced menopause in research animals, according to a new study by researchers at North Carolina State University. The study is a breakthrough in determining how these compounds can cause reproductive health problems, as well as in providing a key building block for how to treat these problems.
The study is the first to show that the actual physical organization of a region of the brain that is important for female reproduction can be significantly altered by exposure to phytoestrogens - or plant-produced chemicals that mimic hormones - during development. Specifically, the study finds that the compounds alter the sex-specific organization of the hypothalamus - a brain region that is essential to the regulation of puberty and ovulation. The study also shows that the phytoestrogens could cause long-term effects on the female reproductive system.
While the study examined the impact of these compounds on laboratory rats, neurotoxicologist Dr. Heather Patisaul - who co-authored the study - says the affected "circuitry" of the brain is similar in both rats and humans. Patisaul is an assistant professor in NC State's Department of Zoology. Her co-author is Heather Bateman, a doctoral student in the department.
Patisaul says this finding is extremely important because, while the changes in brain structure cannot be reversed, "if you understand what is broken, you may be able to treat it." Patisaul says she is in the process of evaluating the effects of these compounds on the ovaries themselves.
Patisaul says that this study is also "a step towards ascertaining the effects of phytoestrogens on developing fetuses and newborns." Patisaul adds that these phytoestrogenic compounds cross the placental barrier in humans and that, while many people are concerned about the effects of man-made compounds on human health, it is important to note that some naturally occurring substances can have similar effects.
In the study, which will be published in an upcoming issue of Neurotoxicology, the researchers exposed newborn rats to physiologically relevant doses of the phytoestrogens genistein and equol, and then looked at reproductive health markers in the rats throughout their adulthood. The neonatal stage of development in rats is comparable to the latter stages of pregnancy for humans, Patisaul says. Genistein is a phytoestrogen that is found in various plants, including soybeans and soy-based foods. Equol is a hormone-like compound that is formed when bacteria found in the digestive system metabolize another phytoestrogen. However, only approximately a third of humans have the necessary bacteria to produce equol.
The study shows that both genistein and equol result in the early disruption of the rats' estrus cycle - which would be corollary to early onset of menopause in a human. The study also showed that genistein caused the early onset of puberty. The disruption of the estrus cycle could stem from problems with the brain or the ovaries, so the researchers decided to determine if the compounds had any effect on brain development or function.
###
Abstract:
"Disrupted female reproductive physiology following neonatal exposure to phytoestrogens or estrogen specific ligands is associated with decreased GnRH activation and kisspeptin fiber density in the hypothalamus"
Authors: Dr. Heather B. Patisaul, Heather L. Bateman, North Carolina State University
Published: July 2008, online by Neurotoxicology
It is well established that estrogen administration during neonatal development can advance pubertal onset and prevent the maintenance of regular estrous cycles in female rats. This treatment paradigm also eliminates the preovulatory rise of gonadotropin releasing hormone (GnRH). It remains unclear, however, through which of the two primary forms of the estrogen receptor (ERα or ERβ) this effect is mediated. It is also unclear whether endocrine disrupting compounds (EDCs) can produce similar effects. Here we compared the effect of neonatal exposure to estradiol benzoate (EB), the ERα specific agonist 1,3,5-tris(4-Hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), the ERβ specific agonist diarylpropionitrile (DPN) and the naturally occurring EDCs genistein (GEN) and equol (EQ) on pubertal onset, estrous cyclicity, GnRH activation, and kisspeptin content in the anteroventral periventricular (AVPV) and arcuate (ARC) nuclei. Vaginal opening was significantly advanced by EB and GEN. By ten weeks postpuberty, irregular estrous cycles were observed in all groups except the control group. GnRH activation, as measured by the percentage of immunopositive GnRH neurons that were also immunopositive for Fos, was significantly lower in all treatment groups except the DPN group compared to the control group. GnRH activation was absent in the PPT group. These data suggest that neonatal exposure to EDCs can suppress GnRH activity in adulthood, and that ERα plays a pivotal role in this process. Kisspeptins (KISS) have recently been characterized to be potent stimulators of GnRH secretion. Therefore we quantified the density of KISS immunolabeled fibers in the AVPV and ARC. In the AVPV, KISS fiber density was significantly lower in the EB and GEN groups compared to the control group but only in the EB and PPT groups in the ARC. The data suggest that decreased stimulation of GnRH neurons by KISS could be a mechanism by which EDCs can impair female reproductive function.
Source: Matt Shipman
North Carolina State University
Visit our pregnancy / obstetrics section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/116962.php>
APA
http://www.medicalnewstoday.com/releases/116962.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




